K. Domanska-Czyz

发表

Prognostic Value of the Immunological Subtypes of Adolescent and Adult T-Cell Lymphoblastic Lymphoma; an Ultra-High-Risk Pro-T/CD2(−) Subtype

J. Walewski, J. Romejko-Jarosińska, W. Michalski, 2021, Cancers.

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up

J. Walewski, A. Borawska, J. Romejko-Jarosińska, 2022, Scientific Reports.

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.

E. Thiel, W. Hiddemann, H. Döhner, 2014, Blood.

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma

J. Zaucha, J. Walewski, A. Pluta, 2022, British journal of haematology.

Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R‐MIV) in patients with primary CNS lymphoma including recent COVID‐19 pandemic experience

J. Walewski, A. Borawska, J. Romejko-Jarosińska, 2023, British journal of haematology.

A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration

R. Siebert, I. Salaverria, J. Walewski, 2018, Modern Pathology.

Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation

W. Tomczak, J. Walewski, J. Romejko-Jarosińska, 2021, Leukemia & lymphoma.

Idiopathic multicentric Castleman disease: pathogenesis, clinical presentation and recommendations for treatment based on the Castleman Disease Collaborative Network (CDCN)

J. Walewski, J. Romejko-Jarosińska, K. Domańska-Czyż, 2021, Acta Haematologica Polonica.

Substantially Improved Outcome of Adult Burkitt Non-Hodgkin Lymphoma and Leukemia Patients with Rituximab and a Short-Intensive Chemotherapy; Report of a Large Prospective Multicenter Trial

E. Thiel, W. Hiddemann, H. Döhner, 2012 .